Business
Biopharma fundraising rebounds as regulatory uncertainty eases and M&A accelerates, boosting valuations and public-market financing. Yet early-stage start-ups still struggle, with investors favoring clinical-stage assets amid cautious VC fund formation and uneven capital access.
The pharmaceutical industry continues to experience significant shifts in sales performance, with some companies achieving remarkable growth while others face stagnation or decline.
As regulatory uncertainty under the Trump administration eases, with dealmaking picking up and biopharma firms delivering good data, financial markets are primed for biopharma investment.
Corporate venture arms can be powerful growth partners, but founders who don’t take time to understand them risk missing their greatest value.
Samsung Next’s corporate venture capital team employs a differentiated investment policy to the average investor, as managing director Jonathan Machado explained.